Market Cap | 302.12M | P/E | - | EPS this Y | 27.10% | Ern Qtrly Grth | - |
Income | -48.88M | Forward P/E | -3.24 | EPS next Y | -57.10% | 50D Avg Chg | 6.00% |
Sales | - | PEG | -0.06 | EPS past 5Y | - | 200D Avg Chg | -10.00% |
Dividend | N/A | Price/Book | 1.31 | EPS next 5Y | 23.10% | 52W High Chg | -63.00% |
Recommedations | 1.80 | Quick Ratio | 18.70 | Shares Outstanding | 51.52M | 52W Low Chg | 72.00% |
Insider Own | 2.31% | ROA | -19.88% | Shares Float | 38.27M | Beta | 1.52 |
Inst Own | 84.25% | ROE | -22.62% | Shares Shorted/Prior | 1.06M/1.09M | Price | 6.60 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 340,114 | Target Price | 8.20 |
Oper. Margin | - | Earnings Date | Nov 7 | Volume | 140,737 | Change | 0.00% |
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
HC Wainwright & Co. | Buy | Aug 20, 24 |
HC Wainwright & Co. | Buy | May 30, 24 |
HC Wainwright & Co. | Buy | May 14, 24 |
Craig-Hallum | Buy | May 13, 24 |
Jefferies | Buy | Apr 12, 24 |
HC Wainwright & Co. | Buy | Mar 7, 24 |
Ladenburg Thalmann | Buy | Dec 27, 23 |
HC Wainwright & Co. | Buy | Oct 16, 23 |
HC Wainwright & Co. | Buy | Aug 11, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
ORBIMED ADVISORS LLC | 10% Owner 10% Owner | Nov 22 | Sell | 2.23 | 87,786 | 195,763 | 11/24/23 | |
Mack David Henry | President and CEO President and CEO | Aug 07 | Option | 0.53 | 85,500 | 45,315 | 165,470 | 08/08/23 |
Mack David Henry | President and CEO President and CEO | Apr 27 | Option | 0.53 | 33,000 | 17,490 | 79,970 | 04/29/22 |
ORBIMED ADVISORS LLC | 10% Owner 10% Owner | Mar 29 | Sell | 21.69 | 474,500 | 10,291,905 | 03/31/22 | |
Mack David Henry | President and CEO President and CEO | Dec 15 | Option | 0.53 | 9,000 | 4,770 | 26,970 | 12/16/21 |